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Buccal mucosa is an attractive route for systemic delivery of drugs since it is rela-
tively permeable with a rich blood supply (1). A drug can be easily applied and locali-
zed to the application site, and can be removed from there if necessary. Attempt has
been made earlier to formulate various mucoadhesive buccal devices, including tablets
(2), films (3), patches (4), disks (5), strips (6), ointments (7) and gels (8). Buccal patches
are highly flexible and thus much more readily tolerated by the patient than tablets. Pat-
ches also ensure more accurate dosing of the drug compared to gels and ointments.
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Mucoadhesive buccal patches containing propranolol hyd-
rochloride were prepared using the solvent casting method.
Chitosan was used as bioadhesive polymer and different
ratios of chitosan to PVP K-30 were used. The patches were
evaluated for their physical characteristics like mass vari-
ation, drug content uniformity, folding endurance, ex vivo
mucoadhesion strength, ex vivo mucoadhesion time, sur-
face pH, in vitro drug release, and in vitro buccal perme-
ation study. Patches exhibited controlled release for a pe-
riod of 7 h. The mechanism of drug release was found to
be non-Fickian diffusion and followed the first-order ki-
netics. Incorporation of PVP K-30 generally enhanced the
release rate. Swelling index was proportional to the con-
centration of PVP K-30. Optimized patches (F4) showed
satisfactory bioadhesive strength of 9.6 ± 2.0 g, and ex vivo
mucoadhesion time of 272 minutes. The surface pH of all
patches was between 5.7 and 6.3 and hence patches should
not cause irritation in the buccal cavity. Patches contain-
ing 10 mg of drug had higher bioadhesive strength with
sustained drug release as compared to patches contain-
ing 20 mg of drug. Good correlation was observed betwe-
en the in vitro drug release and in vitro drug permeation
with a correlation coefficient of 0.9364. Stability study of
optimized patches was done in human saliva and it was
found that both drug and buccal patches were stable.
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During the last decade, bioadhesive polymers received considerable attention as plat-
forms for buccal controlled delivery due to their ability to localize the dosage form in spe-
cific regions to enhance drug bioavailability (9). In the present study, the natural bioadhe-
sive polymer chitosan was selected (10) for the development of controlled release buccal
mucoadhesive devices. Chitosan is the N-deacetylated product of the polysaccharide chitin
(11). Chitosan is gaining increasing importance in the pharmaceutical field due to its good
biocompatibility, after both intravenous and oral administration, and its non-toxicity and
biodegradable (12). From the technological point of view, chitosan has also been demon-
strated to be a promising matrix carrier for sustained drug release (13) and it possesses ex-
cellent film-forming properties (14). In spite of this, only a few studies have so far been per-
formed on the usefulness of chitosan films as drug delivery systems (15).
Propranolol hydrochloride, a non-selective  -adrenergic blocking agent, has been
widely used in the treatment of hypertension, angina pectoris and many other cardio-
vascular disorders (16).
The present study was an attempt to develop chitosan-containing mucoadhesive buc-
cal patches to ensure satisfactory release of propranolol hydrochloride for prolonged peri-
ods. The influence of Polyvinylpyrrolidone K-30 (PVP K-30) and drug concentration on the
drug release and mucoadhesive performance on sheep buccal patches was investigated.
EXPERIMENTAL
Materials
Propranolol hydrochloride (99.86% purity) was a gift sample from Sarabhai Chemi-
cals Ltd., India. Chitosan (140 cps, 85% deacetylation) was a gift sample from the Central
Institute of Fisheries Technology, India. PVP K-30 (S. D. Fine Chemicals, India) was ob-
tained from a commercial source. All other reagents and chemicals used were of analyti-
cal reagent grade.
Preparation of mucoadhesive buccal patches
Patches containing different drug and chitosan proportions were prepared by the
solvent casting method (17). One g of chitosan was dissolved in 100 mL 1.5% (V/V) ace-
tic acid under occasional stirring for 48 h. The resulting viscous chitosan solution was
filtered through nylon gauze to remove debris and suspended particles. To improve patch
performance and release characteristics, a water-soluble hydrophilic additive, PVP K-30,
was added in different concentrations. The drug and PVP K-30 were added into the chi-
tosan solution under constant stirring. Propylene glycol (5%, V/V) was added into the
solution as plasticizer under constant stirring. This viscous solution was left overnight at
room temperature to ensure a clear, bubble-free solution. The solution was poured into a
glass Petri dish (16 cm diameter) and allowed to dry at ambient temperature till a flexi-
ble film was formed. Dried films were carefully removed, checked for any imperfections
or air bubbles and cut into patches of 16 mm in diameter, containing 10 mg or 20 mg of
drug per patch. The patches were packed in aluminum foil and stored in an airtight
glass container to maintain the integrity and elasticity of the patches. Table I shows the
composition of different buccal patches.
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Mass uniformity and folding endurance
Mass uniformity was tested in 10 different randomly selected patches from each batch
and patch thickness was measured at 5 different randomly selected spots using a screw
gauge.
Folding endurance of the patches was determined by repeatedly folding one patch
at the same place till it broke or folded up to 200 times without breaking (18).
Swelling study
Buccal patch was weighed, placed in a 2% agar gel plate (29) and incubated at 37 ± 1
°C. At regular one-hour time intervals (to 3 h), the patch was removed from the Petri
dish and excess surface water was removed carefully using the filter paper. The swollen
patch was then reweighed and the swelling index was calculated (19). The experiments
were carried out in triplicate and average values were reported.
Content uniformity
Drug content uniformity was determined by dissolving the patch by homogeniza-
tion in 100 mL of an isotonic phosphate buffer (pH 6.8) for 8 h under occasional shaking.
The 5 mL solution was taken and diluted with isotonic phosphate buffer pH 6.8 up to 20
mL, and the resulting solution was filtered through a 0.45 mm Whatman filter paper. The
drug content was then determined after proper dilution at 290 nm using a UV-spectro-
photometer (Shimadzu, SPD-10 A VP, Japan) (20). The experiments were carried out in
triplicate and average values were reported.
Ex vivo mucoadhesive strength
Fresh sheep buccal mucosa was obtained from a local slaughterhouse and used within
2 h of slaughter. The mucosal membrane was separated by removing the underlying fat
and loose tissues. The membrane was washed with distilled water and then with iso-
tonic phosphate buffer pH 6.8 at 37 °C. Bioadhesive strength of the patch was measured
(n = 3) on a modified physical balance using the method described by Gupta et al. (21).
Fresh sheep buccal mucosa was cut into pieces and washed with isotonic phosphate
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Table I. Composition of chitosan buccal patches of propranolol hydrochloride
Component
Batch code
Placebo F1 F2 F3 F4 F5 F6 F7
Propranolol hydrochloride (mg) – 640 640 640 640 640 640 320
Chitosan (mg) 1000 1000 1000 1000 1000 1000 1000 1000
PVP K-30 (mg) – – 100 150 175 200 225 175
Acetic acid 1% (m/m) 1.5 1.5 1.5 1.5 1.5 1.5 1.5 1.5
Propylene glycol (%, m/m) – 5 5 5 5 5 5 5
buffer pH 6.8. A piece of buccal mucosa was tied to the open mouth of a glass vial, filled
completely with isotonic phosphate buffer pH 6.8. The glass vial was tightly fitted in the
center of a glass beaker filled with isotonic phosphate buffer (pH 6.8, 37 ± 1 °C). The
patch was stuck to the lower side of the rubber stopper with cyanoacrylate adhesive.
The mass, in gramms, required to detach the patch from the mucosal surface gave the
measure of mucoadhesive strength. The following parameters were calculated from the
bioadhesive strength:
force of adhesion (N) =
bioadhesive strength 9.81×
1000
bond strength (N m–2) =
force of adhesion
disk surface area
The results are reported in Table II.
Ex vivo mucoadhesion time
The ex vivo mucoadhesion time was evaluated (n = 3) after application of the patches
onto freshly cut sheep buccal mucosa (22). The fresh sheep buccal mucosa was fixed in
the inner side of the beaker, above 2.5 cm from the bottom, with cynoacrylate glue. One
side of each patch was wetted with one drop of isotonic phosphate buffer pH 6.8 and
pasted to the sheep buccal mucosa by applying a light force with a fingertip for 30 sec-
onds. The beaker was filled with 500 mL of isotonic phosphate buffer pH 6.8 and was
kept at 37 ± 1 °C. After 2 minutes, a 50 rpm stirring rate was applied to simulate the
buccal cavity environment, and patch adhesion was monitored up to 12 h. The time re-
quired for the patch to detach from the sheep buccal mucosa was recorded as the muco-
adhesion time. The results are shown in Table III.
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Table II. Bioadhesive parameters of propranolol hydrochloride buccal patches F1 to F7
Batch code Bioadhesive strength (g)a Force of adhesion (N) Bond strength (N m–2)
Placebo 21.5 ± 1.8 0.21 1049
F1 12.6 ± 2.4 0.12 615
F2 11.4 ± 1.3 0.11 556
F3 10.1 ± 1.2 0.10 493
F4 9.6 ± 2.0 0.10 469
F5 4.8 ± 0.9 0.05 234
F6 2.9 ± 0.7 0.03 141
F7 13.5 ± 0.7 0.13 659
a Mean ± SD, n = 3.
Surface pH study
The method adopted by Bottenberg et al. (23) was used to determine the surface pH
of the patches. A combined glass electrode was used for this purpose. The patches were
allowed to swell by keeping them in contact with 1 mL of distilled water (pH 6.5 ± 0.1)
for 2 h at room temperature, and pH was noted down by bringing the electrode in con-
tact with the surface of the patch, allowing it to equilibrate for 1 minute.
In vitro release
The USP 23 (24) rotating paddle method was used to study the drug release from
buccal patches. The dissolution medium consisted of 200 mL of isotonic phosphate buf-
fer pH 6.8. The release was performed at 37 ± 0.5 °C, at a rotation speed of 50 rpm. One
side of the buccal patch was attached to a glass disk with instant adhesive (cyanoacry-
late). The disk was put in the bottom of the dissolution vessel so that the patch remained
on the upper side of the disk. Samples (5 mL) were withdrawn at pre-determined time
intervals and replaced with fresh medium. The samples were filtered through 0.45 mm
Whatman filter paper with appropriate dilutions with phosphate buffer pH 6.8 and were
assayed spectrophotometrically at 290 nm (20).
In vitro buccal permeation study
The in vitro study of propranolol hydrochloride permeation through the sheep buc-
cal mucosa was performed using a Keshary-Chien type glass diffusion cell at 37 ± 0.2 °C.
Sheep buccal mucosa was obtained from a local slaughterhouse (used within 2 h of sla-
ughter). Freshly obtained sheep buccal mucosa was mounted between the donor and re-
ceptor compartments so that the smooth surface of the mucosa faced the donor compart-
ment. The patch was placed on the mucosa and the compartments clamped together.
The donor compartment was filled with 1 mL of isotonic phosphate buffer pH 6.8. The
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Placebo 48 ± 1 0.31 ± 0.08 0 705 ± 6 6.32 ± 0.21 212 ± 17
F1 72 ± 1 0.51 ± 0.07 99.34 ± 0.50 300 ± 7 5.90 ± 0.18 188 ± 12
F2 74 ± 1 0.53 ± 0.05 98.90 ± 1.11 285 ± 6 5.70 ± 0.13 176 ± 10
F3 76 ± 1 0.55 ± 0.09 100.38 ± 0.41 270 ± 9 6.02 ± 0.14 174 ± 14
F4 80 ± 0 0.56 ± 0.04 99.65 ± 0.20 272 ± 6 5.93 ± 0.02 168 ± 20
F5 82 ± 1 0.57 ± 0.02 99.68 ± 0.15 195 ± 7 5.81 ± 0.12 160 ± 18
F6 84 ± 1 0.58 ± 0.04 99.00 ± 0.62 165 ± 4 6.05 ± 0.14 152 ± 22
F7 68 ± 1 0.43 ± 0.01 99.95 ± 0.26 430 ± 6 5.92 ± 0.05 223 ± 12
a Mean ± SD, n = 3.
receptor compartment (15 mL capacity) was filled with isotonic phosphate buffer pH 7.4
and the hydrodynamics in the receptor compartment was maintained by stirring with a
magnetic bead at 100 rpm. One mL sample was withdrawn at predetermined time inter-
vals and analyzed for drug content at 290 nm (20).
Stability in human saliva
The stability of optimized patches was tested in natural human saliva with the ap-
proval of the Ethical Committee on 10 volunteers. Human saliva was collected from healthy
volunteers (aged 18–50 years, male and female), free of any disease. Patches were placed
in separate Petri dishes containing 5 mL of human saliva and kept in a temperature-
controlled oven (Hicon, Groover Enterprises, India) at 37 ± 0.2 °C for 6 h. At regular time
intervals (0, 1, 2, 3 and 6 h), the patches were examined for changes in color and shape,
collapse of the patch. Drug content was determined by appropriate dilution of human
saliva in phosphate buffer pH 6.8 and analyzed by spectrophotometry at 290 nm (20).
RESULTS AND DISCUSSION
In the present study, buccal patches for controlled delivery of propranolol hydro-
chloride were developed using chitosan as the base matrix. The patches were prepared
using different ratios of chitosan to PVP K-30 (1:0.1, 1:0.15, 1:0.175, 1:0.2 and 1:0.225 from
batch F1 to F6. PVP K-30 was added to improve the drug release by polymer swelling,
elasticity and film forming properties of the patches. Propylene glycol (5%) was added
as plasticizer. On the basis of bioadhesive strength (9.6 ± 2.0 g) and in vitro drug release
(85.5% in 7 h) from the buccal patches, batch F4 was selected for further study. Batch F7
was prepared from optimized batch (F4) by taking half quantity of the drug to study the
effect of drug concentration in buccal formulations.
The prepared patches were smooth in appearance, uniform in thickness, mass, and
drug content and showed no visible cracks. The patches exhibited good folding endur-
ance (more than 150, Table III). Patch thickness ranged from 0.43 ± 0.01 to 0.58 ± 0.04 mm
and mass ranged from 68 ± 1 to 84 ± 1 mg. Patches had a surface pH of 5.82 ± 0.13 to 6.11
± 0.12. The drug content in the buccal patches ranged from 98.9 ± 1.1 to 100.4 ± 0.4%, in-
dicating the favourable drug loading and patches uniformity with respect to drug con-
tent.
Appropriate swelling behavior of a buccal adhesive system is the essential property
for uniform and prolonged release of the drug and effective mucoadhesion (25). The swel-
ling study indicated that the swelling index was higher in patches containing a higher
amount of PVP K-30. Examination of the patches during the dissolution studies also re-
vealed that the patches showed considerable swelling, especially at higher concentra-
tions of PVP K-30. The weak aqueous solubility of the cationic polymer (chitosan) lim-
ited the swelling of the patches, which was observed in placebo patches. Addition of the
hydrophilic polymer PVP K-30 increased the surface wettability and consequently water
penetration within the matrix.
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Patches did not show any appreciable changes in their shape and form during the 3 h
that they were kept on a 2% agar gel plate. The optimized patch (F4) showed a 28.2
± 1.2% swelling index due to water absorption within 3 h. Swelling behavior of patches
as a function of time is shown in Figure 1. It was observed that medicated patches had a
higher swelling index compared to plain patches. The higher swelling index of medi-
cated patches may be due to the hydrophilic nature of the drug, which dissolves fast
when it comes in contact with the dissolution medium. Figure 2 shows that patches con-
taining PVP (batches F1 to F6) had a higher swelling index than the patches without PVP.
Mucoadhesion may be defined as the adhesion between a polymer and mucus. In
general, mucoadhesion is considered to occur in 3 major stages: wetting, interpenetra-
tion, and mechanical interlocking between mucus and polymer. The strength of muco-
adhesion is affected by various factors such as molecular mass of polymers, contact time
with mucus, swelling rate of the polymer and the biological membrane used in the study
(26). In this study, sheep buccal mucosa was used as biological membrane. Plain patches
showed higher mucoadhesive strength (21.5 ± 1.8 g) than medicated patches. The patch
containing 10 mg of drug (F7) showed higher bioadhesive strength compared to 20 mg
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Fig. 1. Swelling index of buc-
cal patches from batches F1
to F7. Mean ± SD, n = 3.
of drug (F1 to F6). Incorporation of PVP K-30, a water-soluble hydrophilic polymer, and
water-soluble drug reduced significantly the bioadhesive strength of buccal patches. Bio-
adhesive strength of the optimized patch (F4) was found to be 9.6 ± 2.0 g and the force
of adhesion and bond strength were 0.0942 N and 468.75 N m–2, respectively. The impor-
tant bioadhesive parameters of buccal patches are given in Table II.
In vitro release of propranolol hydrochloride from different patches is shown in Fig-
ure 2. The drug released increased linearly with the increasing concentration of PVP-
K-30 from batches F1 to F6. The maximum in vitro release was found to be 99.8 ± 1.3%
over a period of 7 h in batch F6, containing the highest amount of PVP K–30, which
could be attributed to its high rate and extent of swelling. This finding was also sup-
ported by the results of swelling studies where the highest swelling index was also ex-
hibited by batch F6, indicating that the increase in water-soluble polymer PVP-K30 con-
tent results in faster swelling and release from patches (27).
F4 patches with 20 mg of drug showed higher and faster drug release than patches
containing 10 mg of drug (F7). Propranolol hydrochloride (a water soluble drug), dis-
solves easily in a hydrated polymeric environment. Therefore, the higher the loading of
propranolol hydrochloride, the more drug would dissolve inside the hydrated matrices,
resulting in a higher diffusional driving force and faster drug release. These results show-
ed that the drug and PVP K-30 have also a significant effect on release behaviour of the
drug from chitosan-based matrix. The release data were analyzed using the well known
semi-empirical Peppas equation (28):
Mt /M¥ = k tn
where Mt /M¥ is the fractional release of the drug, t denotes the release time, k repre-
sents a kinetic constant, incorporating structural and geometrical characteristics of the
device, and n is the diffusional exponent and characterizes the type of release mecha-
nism during the dissolution process. For non-Fickian release, the value of n falls betwe-
en 0.5 and 1.0 while in the case of Fickian diffusion n = 0.5; for first order release (case II
transport) n = 1, and for supercase II transport n >1. The obtained values of k, n and R2
(coefficient determination) are presented in Table IV. The values of n were estimated by
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Table IV. Kinetic constant (k), release exponent (n) and determination coefficient R2
Batch
Peppas model
k (% h–1) R2 n
F1 0.1722 0.9685 0.666
F2 0.1928 0.988 0.684
F3 0.1986 0.9925 0.7036
F4 0.2023 0.9937 0.7365
F5 0.2104 0.9952 0.7633
F6 0.2163 0.9927 0.7821
F7 0.1841 0.9897 0.6942
linear regression of log (Mt/M) vs. log t, and were between 0.5 and 1.0, indicating that
the release of propranolol hydrochloride was by non-Fickian diffusion. In the kinetics
study, the order of drug release from all batches followed zero-order kinetics.
The surface pH of the patches was determined in order to investigate the possibility
of any side effects, in vivo. Since an acidic or alkaline pH may cause irritation to the buc-
cal mucosa, we attempted to keep the surface pH as close to neutral as possible. The sur-
face pH of all the patches (F1 to F7) was near 6 and hence, these patches should not
cause any irritation in the buccal cavity. Ex vivo mucoadhesion time for the medicated
patches varied from 165 to 430 minutes (Table III), the plain patches showed longer mu-
coadhesion time (705 minutes). Incorporation of PVP K-30 and the drug reduced signifi-
cantly ex vivo mucoadhesion time of the patches. Optimized patches (F4) showed a 272
minutes mucoadhesion time on sheep buccal mucosa.
F4 patches were characterized by moderate swelling, a convenient residence time as
well as adequate drug release. These patches were subject to investigation of in vitro
drug diffusion and stability in human saliva. They showed 71.7% drug permeation in 7 h
through sheep buccal mucosa. Good correlation was observed between in vitro drug re-
lease and in vitro drug permeation with a correlation coefficient of 0.96 (Fig. 3).
Stability studies are usually performed in phosphate buffer solutions whose pH per-
tains to the buccal cavity, but stability studies performed in normal human saliva would
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Fig. 3. Correlation between
in vitro drug release and in
vitro drug permeation.
Table V. Stability study of optimized chitosan buccal patches (batch F4) in human saliva
Sampling time (h) Thickness (mm)a Diameter (mm)a Drug recovered (%)a
0 0.56 ± 0.06 16.0 ± 0.10 99.9 ± 0.1
1 0.56 ± 0.08 16.1 ± 0.10 99.2 ± 0.3
2 0.57 ± 0.07 16.2 ± 0.04 99.2 ± 0.4
3 0.60 ± 0.02 16.3 ± 0.03 99.5 ± 0.3
6 0.60 ± 0.04 16.5 ± 0.10 99.1 ± 0.5
a Mean ± SD, n = 3.
be more appropriate to mimic the stability of drug and device in the oral cavity in vivo.
Therefore, the stability study of optimized patches (F4) was examined in human saliva
and their appearance characteristics, such as color and shape, and drug content in natu-
ral human saliva were evaluated (Table V). Thickness and diameter of patches increased
to 7.1 and 3.1% owing to swelling in human saliva in 6 h studies. No color changes were
observed. The recovery of the drug from all patches was found to be 99.9 ± 0.1% indicat-
ing maximum utilization of the drug incorporated.
CONCLUSIONS
From the present investigation, one can conclude that the optimized buccoadhesive
patches of propranolol hydrochloride with the combination of chitosan and PVP K-30
can meet the ideal requirements for buccal devices, which can be a good way to bypass
the extensive hepatic first pass metabolism.
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S A @ E T A K
Priprava i karakterizacija mukoadhezivnih flastera za bukalnu primjenu
propranolol hidroklorida s kitozanom
VISHNU M. PATEL, BHUPENDRA G. PRAJAPATI i MADHABHAI M. PATEL
Mukoadhezivni flasteri za bukalnu primjenu s propranolol hidrokloridom priprav-
ljeni su koriste}i metodu isparavanja otapala. Kao mukoadhezivni polimer upotrebljen
je kitozan u razli~itim omjerima u odnosu na PVP K-30. Odre|ivana su sljede}a svojstva
flastera: masa, ujedna~enost koli~ine lijeka, savitljivost, ex vivo mukooadhezivnost, ex
vivo vrijeme mukoadhezije, pH na povr{ini, in vitro osloba|anje ljekovite tvari i in vitro
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permeacija. Iz flastera se ljekovita tvar kontrolirano osloba|ala, prema kinetici prvog
reda tijekom 7 h i nije slijedila Fickov zakon difuzije. Upotreba PVP K-30 produljila je
vrijeme osloba|anja. Indeks bubrenja bio je proporcionalan koncentraciji PVP K-30. Sna-
ga bioadhezije optimiranih flastera (F4) bila je 9,6 ± 2,0 g, a ex vivo vrijeme mukoadhezije
272 minute. pH na povr{ini svih flastera bio je izme|u 5,7 i 6,3 pa ne bi trebali iritirati
bukalnu {upljinu. Flasteri sa 10 mg propranolola imali su ve}u bioadhezivnost, a lijek se
iz njih polaganije osloba|ao nego iz flastera sa 20 mg ljekovite tvari. Dobivena je dobra
korelacija izme|u in vitro osloba|anja i in vitro permeacije lijeka (koeficijent korelacije
0,9364). Ispitivanja stabilnosti pokazala su da su i propranolol i flasteri za bukalnu pri-
mjenu stabilni u ljudskoj slini.
Klju~ne rije~i: mukoadhezija, flasteri za bukalnu primjenu, propranolol hidroklorid, bukalna primje-
na, kitozan
S. K. Patel College of Pharmaceutical Education and Research, Ganpat Vidyanagar, Kherva-382711
Mehsana, Gujarat, India
72
V. M. Patel et al.: Design and characterization of chitosan-containing mucoadhesive buccal patches of propranolol hydrochloride,
Acta Pharm. 57 (2007) 61–72.
